February 19, 2021 11:06 AM ESTUpdated February 24, 07:31 AM

Incyte scores speedy FDA review for JAK cream in atopic dermatitis; Lilly backs $90M raise for Regor

Kyle Blankenship

Max Gelman

Senior Editor

John Carroll

Editor & Founder

Incyte’s stalwart JAK inhibitor Jakafi has raced out to blockbuster sales without the safety burden of other drugs in the class. Now, the drugmaker’s quest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Incyte scores speedy FDA review for JAK cream in atopic dermatitis; Lilly backs $90M raise for Regor

Kyle Blankenship

Max Gelman

Senior Editor

John Carroll

Editor & Founder

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

In­cyte scores speedy FDA re­view for JAK cream in atopic der­mati­tis; Lil­ly backs $90M raise for Re­gor

Senior Editor

Editor & Founder

Sign up to read this article for free.

more like this

Incyte scores speedy FDA review for JAK cream in atopic dermatitis; Lilly backs $90M raise for Regor